An observational study in Catheter-Related Infections, sponsored by Hôpital NOVO. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by Hôpital NOVO · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Catheter-Related Infections with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Catheter-Related Infections · France.
Among the 16 studies in Catheter-Related Infections with a site in France, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 14th registered.
113 studies on the registry are indexed under Catheter-Related Infections; 19 are open to participants now.
Browse Catheter-Related Infections studies →4 of the 16 studies in Catheter-Related Infections with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 10 Catheter-Related Infections studies recruiting now, 9 (90%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 250 is above the median of 200 across 23 observational studies indexed under Catheter-Related Infections.
Median enrollment 300 across the 10 interventional studies, 200 across the 6 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 10 most frequent:
Hôpital NOVO is the lead sponsor of 70 studies on the registry; 19 are open to participants now.
Hôpital NOVO has 1 study filed under Catheter-Related Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Catheter-Related Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07258862Hôpital NOVOAnalysis of Microbial Biofilms in Peripheral Venous Catheters and Their Implication in Infectious Risk | 2027-03-28 |
| NCT07388381Centre Hospitalier Universitaire de NiceSuperficial Vein Thrombosis of the Upper Limb in Bacteremia Associated With PICCline and Midline Catheters: Frequency and Clinical Consequences | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Catheter-Related Infections with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Peripheral venous catheters (PVCs) are the most commonly used intravascular medical devices in healthcare establishments. Although essential in patient care, PVCs represent a significant risk factor for nosocomial infections, as shown by the results of the national prevalence survey. While the main pathophysiological mechanisms are known, the specific factors driving the transition from simple colonization to infection remain unclear. This project aims to identify the major factors involved in the occurrence of bacterial infections related to the colonization of peripheral venous catheters.
Peripheral venous catheters (PVCs) are the most commonly used intravascular medical devices in healthcare establishments. In the 2022 national survey on the prevalence of nosocomial infections (NI), out of 151676 patients included, 22.45% had a peripheral venous catheter. Moreover, patients exposed to a PVC are 3 times more likely to suffer a nosocomial infection. Between 2019 and 2023, at national level, there was a significant increase in the proportion of PVC-related bloodstream infection. The pathophysiological mechanisms of catheter-related infections are mainly linked to contamination via the endoluminal route, through manipulations of connectors during perfusion connections, or via the extraluminal route, which is more likely to be associated with faulty catheter placement practices. Finally, even in patients with no clinical signs of infection, culture-negative PVCs show intra- and extra-luminal colonization.
This underscores our lack of understanding of the mechanisms that can lead from simple colonization of the equipment to localized catheter infection or even bacteraemia.
The main objective of this project is to identify the major factors involved in the occurrence of bacterial infections related to the colonization of peripheral venous catheters.
To investigate these mechanisms, the study will focus on the collection of PVCs after clinical removal, followed by molecular and super-resolution microscopy analyses. Catheters either removed by the care team, because they are no longer clinically relevant or for medical reasons, will be collected under aseptic conditions.
Patient hospitalized in a care unit of the NOVO hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Catheter removed because of infection at insertion site
Diagnostic Test: Inflammatory catheters: catheter removed because of infection at insertion site
catheter removed because it is no longer relevant to keep it in place
Device: Non-inflammatory catheters: catheter removed because it is no longer relevant to keep it in place
Verification of inclusion and non-inclusion criteria (at least 2 days and at most 7 days, with or without signs of inflammation). The doctor or a qualified nurse orally informs the patient when catheter removal is planned. The information and non-opposition note are given to the patient, and the information procedure is recorded in the medical record. The catheter is removed and collected under aseptic conditions by the nurses in the various departments, in a dry sterile tube. The tube is then labelled and stored at a maximum of 4°C. The catheter is sent to the hospital's biology laboratory before being collected by the approved carrier for delivery to the ERRMECe laboratory from CYU. All tests are performed in the ERRMECe laboratory. Collected catheters are subsequently analysed to assess the bacterial diversity of biofilms using molecular biology techniques and Next-Generation Sequencing (NGS), in parallel with biofilm structural analysis microscopy using a Scanning Electron Microsc
Verification of inclusion and non-inclusion criteria (at least 2 days and at most 7 days, with or without signs of inflammation). The doctor or a qualified nurse orally informs the patient when catheter removal is planned. The information and non-opposition note are given to the patient, and the information procedure is recorded in the medical record. The catheter is removed and collected under aseptic conditions by the nurses in the various departments, in a dry sterile tube. The tube is then labelled and stored at a maximum of 4°C. The catheter is sent to the hospital's biology laboratory before being collected by the approved carrier for delivery to the ERRMECe laboratory from CYU. All tests are performed in the ERRMECe laboratory. Collected catheters are subsequently analysed to assess the bacterial diversity of biofilms using molecular biology techniques and Next-Generation Sequencing (NGS), in parallel with biofilm structural analysis microscopy using a Scanning Electron Microsc
Bacterial diversity of biofilms in PVCs according to inflammatory symptoms
Relative abundance of bacteria within biofilms present in CVPs as identified by NGS, according to inflammatory symptoms.
Time frame: 15 months
Biofilms structural morphology in PVCs
Qualitative imaging of microbial biofilms in PVCs using Scanning Electron Microscopy
Time frame: 15 months
Bacterial diversity of biofilms in PVCs according to type of substances administered through the vascular route
Relative abundance of bacteria within biofilms present in PVCs as identified by NGS, according to the type of substances received by patients through the vascular route
Time frame: 15 months
Bacterial diversity of biofilms in PVCs according to catheter dwell time
Relative abundance of bacteria within biofilms present in CVPs as identified by NGS, according to catheter dwell time.
Time frame: 15 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Mar 2027, 14 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital NOVO